Global Fractional Flow Reserve Market 2016-2020
About the Fractional Flow Reserve Market
Myocardial fractional flow reserve fractional flow reserve is a new wire-based procedure used in coronary catheterization to measure the pressure differences through a coronary artery stenosis to ascertain the chances of stenosis impeding oxygen delivery to the heart muscle. This technique is carried out through a standard diagnostic catheter at the time of a coronary angiogram. It is a special X-ray test to find out if coronary arteries are narrowed or blocked. Deposits of fat, calcium, cells or proteins can cause plaques and narrow the blood vessels. Depending on the type and severity of the blockage, interventional cardiologists can perform different procedures (angioplasty, bare/drug-eluting stent placement, atherectomy, endarterectomy, and bypass) to improve blood flow.
Technavio’s analysts forecast the global fractional flow reserve market to grow at a CAGR of 14.14% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global fractional flow reserve market for 2016-2020. To calculate the market size, the report considers revenue generated by the following two major segments by applications.
Technavio Announces the Publication of its Research Report – Global Fractional Flow Reserve Market 2016-2020
Technavio recognizes the following companies as the key players in the global fractional flow reserve market: ACIST, Boston Scientific, Opsens, St. Jude Medical, Volcano.
Other Prominent Vendors in the market are: Abbott Laboratories, Asahi Intec, Biosensors, BIOTRONIK international, GE Healthcare, HeartFlow, McKesson, Mennen Medical, Siemens Healthcare, and Terumo.
Commenting on the report, an analyst from Technavio’s team said: “A trend which is propelling market growth is the rising number of clinical trials and regulatory approvals. There has been a growing trend of clinical trials and regulatory approvals in the market. With the growing demand for fractional flow reserve technology, the new companies are continuously seeking ways to gain approvals and launch new products in the market to improve their market share. In January 2014, ACIST's RXi received 510(k) FDA approval for use in gaining intravascular pressure measurements in the diagnosis and treatment of peripheral artery disease and CAD.”
According to the report, a key growth driver is the increased need for diagnosis of coronary artery diseases (CAD). There has been an increased need for a suitable procedure to diagnose the growing prevalence of CAD. Coronary angiography is the standard procedure used for diagnosis of CAD. However, the standard coronary angiography with visual assessment and quantitative coronary angiography alone cannot accurately predict the exact lesion that is causing ischemia. These methods may not provide the clear picture about the severity and hemodynamic significance of lesions. Several studies state that the coronary angiogram is limited and does not measure the extent to which a stenosis is hampering the blood flow. Therefore, the demand for new diagnosis techniques such as fractional flow reserve has increased.
Further, the report states that one challenge that could impact market growth adversely is the stringent regulatory environment.
ACIST, Boston Scientific, Opsens, St. Jude Medical, Volcano, Abbott Laboratories, Asahi Intec, Biosensors, BIOTRONIK international, GE Healthcare, HeartFlow, McKesson, Mennen Medical, Siemens Healthcare, Terumo.